Non-profit product development partnership and generic manufacturer agree to produce new TB drug for countries with high incidence of TB
NEW YORK and MUMBAI (October 28, 2019)—Non-profit drug developer TB Alliance has granted Macleods Pharmaceuticals Limited a non-exclusive license to manufacture the anti-TB drug pretomanid as part of the three-drug “BPaL” regimen. Pending regulatory approvals, Macleods has agreed to commercialize the anti-tuberculosis (TB) medicine in approximately 140 countries and territories.
“TB Alliance is committed to ensuring an affordable, sustainable and competitive market for all our new TB products,” said Mel Spigelman, president and CEO, TB Alliance. “We are proud to partner with Macleods, which has a strong record of delivering high-quality, affordable tuberculosis medicines.”
“Our zeal to bridge unmet needs ensures that we make Tomorrow’s Medicine Available Today. This important collaboration with TB Alliance will ensure accessibility of pretomanid in countries where it is needed the most,” said Vijay Agarwal, business development director at Macleods.
TB Alliance has previously collaborated with Macleods on the introduction of child-friendly formulations of first-line TB medicines. Since launched in 2015, more than one million treatment courses have been ordered by 94 countries, which represent approximately 95% of the global childhood TB burden.1
About TB Alliance